MK-677

Ibutamoren — an oral growth-hormone secretagogue with one solid trial and a long list of open questions.

Evidence tier: B-/C (a genuine long-term human RCT exists, but not for the physique/anti-aging uses it's sold for, and it surfaced real metabolic harms) · Regulatory status in Canada: not approved; grey-market/"research chemical" · Community risk profile: high — orally active, easy to take daily, with documented effects on glucose metabolism.

B

What it is

MK-677 (ibutamoren) is an orally active growth-hormone secretagogue — it stimulates GH and IGF-1 release by mimicking ghrelin. Because it's a pill (not an injection) and raises GH markers, it's popular for muscle, recovery, sleep, and "anti-aging." It is not an anabolic steroid and not a peptide, but it's discussed in the same communities.

What People Use it For

  • Community: muscle gain, appetite/bulking, sleep quality, skin/recovery, "anti-aging" — taken daily, orally, often for long periods.

  • Marketed as a convenient GH-axis booster without injections.

What The Evidence Shows

Unusually for this space, there's a real long-term human trial:

  • A 2-year randomized controlled trial in older adults (Nass et al., Annals of Internal Medicine 2008) showed MK-677 raised GH/IGF-1 and increased lean mass — but also increased blood glucose and reduced insulin sensitivity, and did not demonstrate the functional benefits people assume.

  • What that means: the compound does what it says to the GH axis, but the same trial that proves the effect also documents a metabolic cost (glucose/insulin), and it did not establish the physique/anti-aging benefits it's sold for.

  • Tier B-/C hybrid: better human evidence than most grey-market compounds — and that evidence is a caution as much as a validation.

Regulatory Status - Canada

Not approved by Health Canada. Sold as a "research chemical / not for human use" — legal shield, not a safety statement. WADA-prohibited, relevant for competitive athletes.

Risks & Red Flags

  • Insulin resistance / raised blood glucose — documented in the 2-year RCT; a real concern for anyone with diabetes risk, prediabetes, or metabolic syndrome.

  • Fluid retention, edema, joint pain — consistent with GH-axis stimulation.

  • Increased appetite (ghrelin mimetic) — intended by some users, unwanted by others.

  • IGF-1 elevation: chronic elevation raises theoretical concerns relevant to cancer risk; worth weighing with a clinician.

  • Heart-failure signal: the older-adult trial noted concern in a subgroup; relevant for anyone with cardiac risk.

Sourcing red flags

  • Unapproved, unverified grey-market product; identity/purity/dose unconfirmed.

  • "99% purity" ≠ potency or identity (see glossary).

  • Oral dosing doesn't make sourcing safer — the vial/tablet is still unverified.

New case reports (2025–2026) add organ-level harms.Two recent case reports sharpen the risk picture beyond the known water-retention / insulin-resistance / raised-IGF-1 concerns: a 2025 BMJ Case Reports report of MK-677-induced hepatotoxicity (liver injury), and a 2026 Cureusreport of spontaneous splenic rupture in a user of performance-enhancing compounds including a growth-hormone secretagogue. Case reports are low on the evidence hierarchy — but for a compound with no approved use and no long-term human safety data, case reports of serious organ events are exactly the signal that matters.

The Honest Bottom Line

MK-677 (ibutamoren) is better-studied than most compounds in the recovery/GH space — there's a real randomized trial (Nass 2008) showing it raises GH and IGF-1 and increased lean mass in older adults. That's why it sits at Tier B rather than C. But "raises a hormone" is not the same as "improves an outcome that matters," and the same trial flagged concerns: increased appetite, fluid retention, raised blood glucose, and a heart-failure signal in a frail subgroup.

It's sold as a research chemical, not an approved drug, so the sourcing and mislabeling risks apply in full. The honest read: a legitimate GH-axis effect exists, the long-term safety picture doesn't, and driving your GH/IGF-1 axis upward for years without monitoring is not a small decision.

How To Lower Your Risk

  • Use the real data: MK-677 reliably raises GH/IGF-1 and reliably worsens glucose metabolism. If you have any diabetes/metabolic risk, that trade-off is the headline.

  • This is endocrine manipulation, not a supplement — effects on the GH/IGF-1 axis don't fully reverse the moment you stop (see rescue-gap page).

  • Monitor glucose if using, and tell a clinician — especially with metabolic, cardiac, or cancer-risk history (see clinician page).

  • Athletes: WADA-prohibited — a doping-control issue as well as a health one.

  • Third-party testing minimum if sourcing grey-market.



Sources

  1. Nass R, et al. Effects of an Oral Ghrelin Mimetic (MK-677) on Body Composition and Clinical Outcomes in Healthy Older Adults: a 2-year randomized controlled trial. Ann Intern Med. 2008. doi:10.7326/0003-4819-149-9-200811040-00003

  2. BMJ Case Rep 2025 — Hepatotoxicity induced by MK-677 — 10.1136/bcr-2025-265728

  3. Cureus 2026 — Spontaneous splenic rupture w/ performance-enhancing compounds — 10.7759/cureus.106106

DOI verified via CrossRef for this project. Note: this trial studied older adults for functional outcomes — not the physique/anti-aging use MK-677 is marketed for — and documented raised glucose/reduced insulin sensitivity alongside the lean-mass gain.

‹ TB-500

Orforglipron ›


Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.